Back

Prognostic significance of low alanine aminotransferase in patients with transthyretin amyloid cardiomyopathy

30 August 2026 (11:33 - 11:45)
Organised by: Logo
Congress Presentation Part of: New directions in cardiac amyloidosis Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Chern Hsiang Choy

Queen Elizabeth Hospital Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension
Doctor K. Alexander (Palo Alto, US)
Abstract Slides Video
Presentation thumbnail
Low aortic valve calcium score as an imaging red flag for concomitant transthyretin cardiac amyloidosis in severe aortic stenosis: A CAUSATIVE study subanalysis
Doctor A. Cantone (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac amyloidosis exhibits a distinct PAR2-linked transcriptional program
Ms E. Ghanbari (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Predictors of recurrent ischemic stroke in cardiac amyloidosis
Mr C. Ng (Leiden, NL)
Abstract Slides Video

Access the full session

Session thumbnail
New directions in cardiac amyloidosis
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 11:33 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic value of cardiac biomarkers in patients with transthyretin deposition cardiac amyloidosis.
29 June 2021
thumbnail
Congress Presentation
Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure
29 June 2021
thumbnail
Congress Presentation
Prognostic impact of follow-up serum albumin after acute myocardial infarction
30 June 2021
thumbnail
Congress Presentation
Mortality & inpatient hospitalizations amongst patients with cardiac light-chain amyloidosis: results from a US administrative claims database
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources